|
Colorectal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Our study showed that PDGF-D was highly expressed in CRC tissues and was positively associated with the clinicopathological features.
|
28035069 |
2017 |
|
Colorectal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
In addition, suppression of ZIC5 or PDGFD expression decreased levels of phosphorylated focal adhesion kinase (FAK) and signal transducer and activator of transcription 3 (STAT3) which are associated with PCa and CRC aggressiveness.
|
29024195 |
2017 |
|
Colorectal Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Possible Role and Therapeutic Target of PDGF-D Signalling in Colorectal Cancer.
|
30836770 |
2019 |
|
Colorectal Carcinoma
|
0.330 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Coronary Arteriosclerosis
|
0.320 |
Biomarker
|
disease |
CTD_human |
A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease.
|
21378988 |
2011 |
|
Coronary Arteriosclerosis
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
A case-control study provides evidence of association for a common SNP rs974819 in PDGFD to coronary heart disease and suggests a sex-dependent effect.
|
22704460 |
2012 |
|
Coronary Arteriosclerosis
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Associations between the CDKN2A/B, ADTRP and PDGFD polymorphisms and the development of coronary atherosclerosis in Japanese patients.
|
24573017 |
2014 |
|
Coronary Artery Disease
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
A case-control study provides evidence of association for a common SNP rs974819 in PDGFD to coronary heart disease and suggests a sex-dependent effect.
|
22704460 |
2012 |
|
Coronary Artery Disease
|
0.320 |
Biomarker
|
disease |
CTD_human |
The CAD-associated SNP in the PDGFD locus showed tissue-specific cis expression quantitative trait locus effects.
|
21378988 |
2011 |
|
Coronary Artery Disease
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
CAD association was replicated for three GWAS-identified loci (1p13.3/SORT1 (rs599839), 9p21.3/CDKN2A/2B (rs4977574), and 11q22.3/ PDGFD (rs974819)) in Koreans.
|
23364394 |
2013 |
|
Lung Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
PDGF-D expression is down-regulated by TGFβ in fibroblasts.
|
25280005 |
2014 |
|
Cirrhosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
PDGF-D expression is down-regulated by TGFβ in fibroblasts.
|
25280005 |
2014 |
|
Chronic Lung Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
PDGF-D expression is down-regulated by TGFβ in fibroblasts.
|
25280005 |
2014 |
|
Glomerulonephritis
|
0.210 |
Biomarker
|
disease |
BEFREE |
Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis.
|
16510766 |
2006 |
|
Glomerulonephritis
|
0.210 |
Biomarker
|
disease |
RGD |
Thus, podocyte-specific overexpression of PDGF-D caused mesangioproliferative disease, glomerulosclerosis, and crescentic glomerulonephritis.
|
21866094 |
2011 |
|
Liver Cirrhosis
|
0.200 |
Biomarker
|
disease |
RGD |
Pro-fibrogenic potential of PDGF-D in liver fibrosis.
|
17397961 |
2007 |
|
Myocardial Infarction
|
0.200 |
Biomarker
|
disease |
RGD |
Platelet-derived growth factor involvement in myocardial remodeling following infarction.
|
21767547 |
2011 |
|
Mesangial proliferative glomerulonephritis
|
0.200 |
Therapeutic
|
disease |
RGD |
PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis.
|
17308324 |
2007 |
|
Mesangial proliferative glomerulonephritis
|
0.200 |
Biomarker
|
disease |
RGD |
A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis.
|
12937299 |
2003 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
Prostate carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
These results provided a novel mechanism by which PDGF-D promotes EMT, which in turn increases tumor growth, and these results further suggest that PDGF-D could be a novel therapeutic target for the prevention and/or treatment of prostate cancer.
|
18403754 |
2008 |
|
Prostate carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
We identify the uPA cleavage site between the CUB and PDGF domains of the full-length PDGF D by mutational analysis and show that PDGF D and uPA colocalize in human prostate carcinoma.
|
15988036 |
2005 |
|
Prostate carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Furthermore, knockdown of ZIC5 or PDGFD enhanced death of PCa and CRC cells induced by the anti-cancer drugs docetaxel or oxaliplatin, respectively.
|
29024195 |
2017 |
|
Prostate carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Here, we identified PDGF-D as a ligand for β-PDGFR in PCa and discovered matriptase as its regulator.
|
21098708 |
2010 |
|
Prostate carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Moreover, conditioned medium from PC3 PDGF-D cells significantly increased the tube formation of human umbilical vein endothelial cells, which was inhibited by B-DIM treatment concomitant with reduced full-length and active form of PDGF-D. Our results suggest that B-DIM could serve as a novel and efficient chemopreventive and/or therapeutic agent by inactivation of both mTOR and Akt activity in PDGF-D-overexpressing prostate cancer.
|
18339874 |
2008 |